

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))		Attorney Docket No. 50047/019002 Serial No. 10/796,947 Applicant Amar et al. Filing Date March 10, 2004 Group 1653 IDS Filed September 17, 2004				
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
MKJ	Myokai et al., "A novel lipopolysaccharide-induced transcription factor regulating tumor necrosis factor $\alpha$ gene expression: Molecular cloning, sequencing, characterization, and chromosomal assignment," <i>Proc. Natl. Acad. Sci. USA</i> , 96:4518-4523 (1999).					
	Neumann et al., "Gene transfer into mouse lymphoma cells by electroporation in high electric fields," <i>EMBO J.</i> , 1(7):841-845 (1982).					
	Polyak et al., "A model for p53-induced apoptosis," <i>Nature</i> , 389(6648):300-305 (1997).					
	Smith and Waterman, "Comparison of Biosequences," <i>Adv. Appl. Math.</i> 2:482-489(1981).					
	Suganuma et al., "A New Process Of Cancer Prevention Mediated Through Inhibitor Of Tumor Necrosis Factor $\alpha$ Expression," <i>Cancer Res.</i> , 56(16):3711-3715 (1996).					
	Sugarmen et al., "Recombinant Human Tumor Necrosis Factor- $\alpha$ : Effects on Proliferation of Normal and Transformed Cells in Vitro," <i>Science</i> , 230(4728):943-945 (1985).					
	Talmadge et al., "Immunomodulatory Properties of Recombinant Murine and Human Tumor Necrosis Factor," <i>Cancer Res.</i> , 48(3):544-550 (1988).					
	Tang et al., "Identification and functional characterization of a novel binding site on TNF- $\alpha$ promoter," <i>Proc. Natl. Acad. Sci. USA</i> , 100(7):4096-4101 (2003).					
	Uglieri et al., "Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor- $\alpha$ gene promoter," <i>Tissue Antigens</i> , 52(4):359-367 (1998).					
	Vousden and Lu, "Live or Let Die: The Cell's Response to p53," <i>Nat. Rev. Cancer</i> , 2(8):594-604 (2002).					
↓	Xaus et al., "LPS induces apoptosis in macrophages mostly through the autocrine production of TNF- $\alpha$ ," <i>Blood</i> , 95(12):3823-3831 (2000).					
EXAMINER <i>Michelle K. [Signature]</i>			DATE CONSIDERED <i>3/15/07</i>			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SEP 20 2004 PATENT & TRADEMARK OFFICE (37 C.F.R. § 1.98(b))		INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Attorney Docket No. 50047/019002 Serial No. 10/796,947 Applicant Amar et al. Filing Date March 10, 2004 Group 1653 IDS Filed September 17, 2004		
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
MKJ	6,566,501	5/20/03	Amar	530	350	4/12/00
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
MKJ	Adams and Cory, "The Bcl-2 Protein Family: Arbiters of Cell Survival," <i>Science</i> , 281(5381):1322-1326 (1998).					
	Alexander et al., "Treatment with Recombinant Human Tumor Necrosis Factor-Alpha Protects Rats Against the Lethality, Hypotension, and Hypothermia of Gram-Negative Sepsis," <i>J. Clin. Invest.</i> , 88:34-39 (1991).					
	Amar and Han, "Regulation of tumour necrosis factor- $\alpha$ gene expression," <i>Appl. Genomics Proteomics</i> 1(1):31-44 (2002).					
	Beutler and Cerami, "The Biology of Cachectin/TNF—A Primary Mediator of the Host Response," <i>Ann. Rev. Immunol.</i> , 7:625-655 (1989).					
	Brugarolas et al., "Radiation-induced cell cycle arrest compromised by p21 deficiency," <i>Nature</i> , 377(6549):552-557 (1995).					
	Capecchi, M.R., "High Efficiency Transformation by Direct Microinjection of DNA into Cultured Mammalian Cells," <i>Cell</i> , 22(2 Pt. 2):479-488 (1980).					
	Cepko et al., "Construction and Applications of a Highly Transmissible Murine Retrovirus Shuttle Vector," <i>Cell</i> , 37(3):1053-1062 (1984).					
	Donis-Keller, H., "Phy M: an RNase activity specific for U and A residues useful in RNA sequence analysis," <i>Nucleic Acids Res.</i> , 8(14):3133-3142 (1980).					
	Drouet et al., "Enhancers and transcription factors controlling the inducibility of the tumor necrosis factor- $\alpha$ promoter in primary macrophages," <i>J. Immunol.</i> , 147(5):1694-1700 (1991).					
	El-Delry et al., "WAF1, A Potential Mediator of p53 Tumor Suppression," <i>Cell</i> , 75(4):817-825 (1993).					
	Felgner et al., "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure," <i>Pro. Natl. Acad. Sci. USA</i> , 84:7413-7417 (1987).					
✓	Galas and Schmitz, "DNAase footprinting: a simple method for the detection of protein-DNA binding specificity," <i>Nucleic Acids Res.</i> , 5(9):3157-3170 (1978).					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))		Attorney Docket No. 50047/019002 Serial No. 10/796,947 Applicant Amar et al. Filing Date March 10, 2004 Group 1653 IDS Filed September 17, 2004				
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
MKJ	Graham and van der Eb, "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA," <i>Virology</i> , 52(2):456-467 (1973).					
	Hornig et al., "TIRAP: an adapter molecule in the Toll signaling pathway," <i>Nat. Immunol.</i> , 2(9):835-841 (2001).					
	IUPAC Commission on the Nomenclature of Organic Chemistry and IUPAC-IUB Commission on Biochemical Nomenclature, "Nomenclature of $\alpha$ -Amino Acids (Recommendations, 1974)," <i>Biochemistry</i> 14(2):449-462 (1975).					
	Kinzler and Vogelstein, "Life (and death) in a malignant tumour," <i>Nature</i> , 379(6560):19-20 (1996).					
	Ko and Prives, "p53: puzzle and paradigm," <i>Genes &amp; Dev.</i> , 10(9):1054-1072 (1996).					
	Ksontini et al., "Disparate Roles for TNF- $\alpha$ and Fas Ligand in Concanavalin A-Induced Hepatitis," <i>J. Immunol.</i> , 160:4082-4089 (1998).					
	Levine, A.J., "p53, the Cellular Gatekeeper for Growth and Division," <i>Cell</i> , 88(3):323-331 (1997).					
	Li et al., "Nitric oxide-induced genotoxicity, mitochondrial damage, and apoptosis in human lymphoblastoid cells expressing wild-type and mutant p53," <i>Proc. Natl. Acad. Sci. USA</i> , 99(16):10364-10369 (2002).					
	McClane et al., "Functional Consequences of Adenovirus-Mediated Murine Pancreatic Gene Transfer," <i>Hum. Gene Ther.</i> , 8(6):739-746 (1997).					
	Miyashita and Reed, "Tumor Suppressor p53 Is a Direct Transcriptional Activator of the Human <i>Bax</i> Gene," <i>Cell</i> , 80(2):293-299 (1995).					
	Morris et al., "A peptide carrier for the delivery of biologically active proteins into mammalian cells," <i>Nat. Biotechnol.</i> , 19(12):1173-1176 (2001).					
↓	Munshi et al., "Lipopolysaccharide-Induced Apoptosis of Endothelial Cells and Its Inhibition by Vascular Endothelial Growth Factor," <i>J. Immunol.</i> , 168(11):5860-5866 (2002).					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						